Informace o publikaci

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Autoři	CHANAN-KHAN Asher CRAMER Paula DEMIRKAN Fatih FRASER Graeme SILVA Rodrigo Santucci GROSICKI Sebastian PRISTUPA Aleksander JANSSENS Ann MAYER Jiří BARTLETT Nancy L DILHUYDY Marie-Sarah PYLYPENKO Halyna LOSCERTALES Javier AVIGDOR Abraham RULE Simon VILLA Diego SAMOILOVA Olga PANAGIOTIDIS Panagiots GOY Andre MATO Anthony PAVLOVSKY Miguel A KARLSSON Claes MAHLER Michelle SALMAN Mariya SUN Steven PHELPS Charles BALASUBRAMANIAN Sriram HOWES Angela HALLEK Michael
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	Lancet Oncology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1016/S1470-2045(15)00465-9
Obor	Onkologie a hematologie
Klíčová slova	BRUTON TYROSINE KINASE; MANTLE CELL LYMPHOMA; INHIBITOR IBRUTINIB; PCI-32765; BTK; CYCLOPHOSPHAMIDE; FLUDARABINE; MALIGNANCY; DISEASE; TRIAL
Popis	Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma. Interpretation In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile.